Sushila R Dalal
Overview
Explore the profile of Sushila R Dalal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
499
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
St-Pierre J, Choi D, Fear E, Choi N, Mathew A, Cohen R, et al.
Dig Dis Sci
. 2025 Mar;
PMID: 40048134
Background: Mirikizumab, an anti-p19IL-23 monoclonal antibody, has shown efficacy and safety in treating moderately to severely active ulcerative colitis (UC) in clinical trials. We assessed the effectiveness and safety of...
2.
Akiyama S, Cohen N, Ollech J, Traboulsi C, Rodriguez T, Rai V, et al.
Crohns Colitis 360
. 2024 Sep;
6(3):otae045.
PMID: 39347443
Background: The modified pouchitis disease activity index (mPDAI) based on clinical symptoms and endoscopic findings is used to diagnose pouchitis, but validated instruments to monitor pouchitis are still lacking. We...
3.
Akiyama S, Ollech J, Cohen N, Traboulsi C, Rai V, Glick L, et al.
Inflamm Bowel Dis
. 2024 Jun;
31(1):63-71.
PMID: 38916136
Background: Patients with inflammatory bowel disease (IBD) who undergo proctocolectomy with ileal pouch-anal anastomosis may develop pouchitis. We previously proposed a novel endoscopic classification of pouchitis describing 7 phenotypes with...
4.
Cohen N, Choi D, Garcia N, Choi N, Picker E, Krugliak Cleveland N, et al.
Dig Dis Sci
. 2023 Dec;
69(2):579-587.
PMID: 38087126
Background: Ozanimod is a first-in-class Sphingosine-1-phosphate (S1P) receptor modulator approved for the treatment of moderately to severely active ulcerative colitis (UC). Real world data describing use of ozanimod are limited....
5.
Friedberg S, Choi D, Hunold T, Choi N, Garcia N, Picker E, et al.
Clin Gastroenterol Hepatol
. 2023 Mar;
21(7):1913-1923.e2.
PMID: 36898598
Background & Aims: Upadacitinib is a novel selective Janus kinase 1 inhibitor that has shown efficacy in the treatment of moderate to severe ulcerative colitis (UC) and Crohn's disease (CD),...
6.
Halper-Stromberg A, Dalal S
Clin Colon Rectal Surg
. 2023 Feb;
36(2):120-126.
PMID: 36844713
Inflammatory bowel diseases (IBDs) result from dysregulated immune responses to environmental and microbial triggers in genetically susceptible hosts. Many clinical observations and animal studies support the role of the microbiome...
7.
Cohen N, Steinberg J, Silfen A, Traboulsi C, Rodriguez T, Singer J, et al.
Dig Dis Sci
. 2022 Oct;
68(4):1464-1472.
PMID: 36242686
Background: Recent real-world effectiveness studies investigating tofacitinib have been encouraging. Questions remain regarding the long-term effectiveness and safety of tofacitinib, effect on endoscopic remission rates, histologic changes, and alterations in...
8.
Cohen N, Dalal S, Choi D, Rubin D
ACG Case Rep J
. 2022 Aug;
9(7):e00832.
PMID: 35919406
Ozanimod has recently received US Food and Drug Administration approval for moderate-to-severe ulcerative colitis. Treatment of acute severe colitis remains a clinical challenge, and although many patients respond to cyclosporine...
9.
Akiyama S, Ollech J, Traboulsi C, Rai V, Glick L, Yi Y, et al.
Dig Dis Sci
. 2022 Mar;
67(8):4020-4031.
PMID: 35288827
Background: The endoscopic appearance in patients with "pouchitis" after ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC) can be quite heterogenous. Patients with an endoscopic phenotype resembling Crohn's disease (CD)...
10.
Ayoub F, Odenwald M, Micic D, Dalal S, Pekow J, Cohen R, et al.
Intest Res
. 2022 Feb;
20(2):240-250.
PMID: 35124951
Background/aims: Perianal fistulas are a debilitating manifestation of Crohn's disease (CD). Despite the advent of anti-tumor necrosis factor (anti-TNF) therapy, the medical management of fistulizing CD continues to be challenged...